Market Research Report
mHealth App Market By Type (Fitness, Lifestyle Management, Nutrition & Diet, Women's Health, Healthcare Providers, Disease Management) And Segment Forecasts, 2014 - 2025
|Published by||Grand View Research, Inc.||Product code||557215|
|Published||Content info||90 Pages
Delivery time: 2-3 business days
|mHealth App Market By Type (Fitness, Lifestyle Management, Nutrition & Diet, Women's Health, Healthcare Providers, Disease Management) And Segment Forecasts, 2014 - 2025|
|Published: August 14, 2017||Content info: 90 Pages||
The global mHealth market is expected to reach USD 111.8 billion by 2025, growing at a CAGR of 44.2%, according to a new report by Grand View Research, Inc. The need to reduce long waiting periods in order to access health care facilities from specialists is the primary driver responsible for the adoption of mHealth.
The availability of applications for consumers are continuing to grow rapidly, especially healthcare apps. These applications assist users in self-management of wellness, disease and chronic abnormalities. This has led to the patient - playing an important and active role in staying informed and updated on their own healthcare decisions, contributing to the rise in adoption of mHealth apps globally.
Healthcare is gradually transitioning towards a precision-based model, better known as a "personalized medicine" model. mHealth is becoming a widespread trend due to the introduction of technologies such as EMR, remote monitoring, and other communication platforms.
mHealth leverages the 4Ps of healthcare delivery, that is personalized, predictive, participatory, and preventive, to ensure delivery of optimal care to its users. In addition, growing penetration of smartphones, especially in low- & middle-income countries and growing focus on utilizing mobile technology to leverage healthcare delivery and ensure a population health plan is anticipated to benefit the market.
Some of the major market participants in the mHealth apps market are Abbott Laboratories; Johnson & Johnson; AstraZeneca; F. Hoffmann-La Roche AG; Novartis AG; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Merck and Co., Inc.; Pfizer; and Sanofi.